Analysis of Paediatric Treatments With multiFiltratePRO
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: CVVHD treatment in paediatric mode with multiFiltratePRO.
- Who it may be relevant to
- Registry conditions: Renal Failure, CVVHD. Basic parameters: up to 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Germany
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Efficacy and Safety of Paediatric CVVHD Treatment With MultiFiltratePRO: A Prospective Multicenter Study
Overview
This clinical study evaluates the performance of the MultifiltratePro in pediatric mode for Continuous Venovenous Hemodiafiltration (CVVHD) in children. Its primary aim is to assess the efficacy of the MultifiltratePro in paediatric mode, specifically in achieving at least 80% of the prescribed effluent dose within 72 hours. Additionally, the study focuses on the safety of this mode in a paediatric setting, closely monitoring for clinical adverse events, hemodynamic instability, and electrolyte imbalances. Paediatric patients with body weights between 8kg and 40kg will be treated with the MultifiltratePro for a period of up to 10 days, with the treatment duration and approach being tailored to the severity of each patient's condition.
Interventions
- Device CVVHD treatment in paediatric mode with multiFiltratePRO
Treatment of acute kidney injury paediatric patients with continuous veno-venous haemodiafiltration (CVVHD) in paediatric mode with multiFiltratePRO
Primary outcome measures
- Effluent dose [Time frame: 0 hours and 72 hours after start of treatment]
Eligibility criteria
Inclusion criteria
General:
- Paediatric Patients:
- Informed consent signed and dated by legal representative and investigator/ authorized physician.
- The minors have received the information referred to in Article 63(2) MDR in a way adapted to their age and mental maturity and from investigators or members of the investigating team who are trained or experienced in working with children.
- The explicit wish of a minor who is capable of forming an opinion and assessing the information referred to in Article 63(2) MDR to refuse participation in, or to withdraw from, the clinical investigation at any time, is respected by the investigator.
Study-specific:
- Estimated life expectancy greater than 3 days
- Children under 18 years
- Body weight ≥8kg and <40kg
- Patients with clinical indication for CVVHD
Exclusion criteria
General:
- Any conditions which could interfere with the patient's ability to comply with the study
- Patient or legal representative is not able to give informed consent according to European Medical Device Regulation and corresponding national regulations
- In case of female patients: pregnancy or lactation period
- Participation in an interventional clinical study during the preceding 30 days
- Previous participation in the same study
Study-specific:
- Hypersensitivity to heparin or known history of heparin induced thrombocytopenia (HIT Type II)
- Uncontrolled bleeding and coagulation disorders
- Decision to limit therapeutic interventions
- Inability to establish the required vascular access
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Germany · 1 center
- Universitätsklinikum Frankfurt — Frankfurt
Identifiers
NCT: NCT06603324 · CVVHD-PED-01-EU